Please assess the completion status of the following clinical trial:

Trial Title: Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 9 to 23 months at the time of receipt of the first dose of Menactra vaccine during the study period.

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- Study Group (Type: None): Participants must have received Menactra Vaccine according to routine clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).